Enhanced disease modeling in space revolutionizes drug development by revealing key molecular mechanisms that traditional models fail to capture, leading to more effective and targeted therapies. By enabling specific testing of disease pathways, it allows scientists to identify novel drug targets at early stages, significantly reducing failure rates in clinical trials. ​

This deeper molecular understanding helps uncover previously hidden biomarkers, improving diagnostics and personalized medicine. With high-throughput screening in microgravity, drug efficacy and resistance can be tested in a more physiologically relevant environment, accelerating innovation. Ultimately, this approach leads to faster drug discovery, better treatments, and improved disease management, transforming human health worldwide.​